Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study

References

• MorstynGCampbellLSouzaLMEffect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapyLancet1988185876676722895212
   PubMed Web of Science ®Google Scholar
• CrawfordJOzerHStollerRReduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancerN Engl J Med199132531641701711156
   PubMed Web of Science ®Google Scholar
• Trillet-LenoirVGreenJManegoldCRecombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapyEur J Cancer199329A33193247691119
   PubMed Web of Science ®Google Scholar
• KudererNMDaleDCCrawfordJLymanGHImpact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic reviewJ Clin Oncol200725213158316717634496
   PubMed Web of Science ®Google Scholar
• HeuserMGanserABokemeyerCAmerican Society of Clinical OncologyNational Comprehensive Cancer NetworkEuropean Organization for Research and Treatment of CancerUse of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelinesSemin Hematol200744314815617631179
   PubMed Web of Science ®Google Scholar
• LocatelliFPedrazzoliPRecombinant human G-CSF: how wide is the field of clinical applicability?Haematologica19958031992057545634
   PubMed Web of Science ®Google Scholar
• Trillet-LenoirVGreenJManegoldCRecombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapyEur J Cancer199329A33193247691119
   PubMed Web of Science ®Google Scholar
• GabriloveJLJakubowskiAScherHEffect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urotheliumN Engl J Med198831822141414222452983
   PubMed Web of Science ®Google Scholar
• VogelCLWojtukiewiczMZCarrollRRFirst and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III studyJ Clin Oncol20052361178118415718314
   PubMed Web of Science ®Google Scholar
• Timmer-BonteJNAdangEMSmitHJCost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancerJ Clin Oncol200624192991299716682725
   PubMed Web of Science ®Google Scholar
• GreenMDKoelblHBaselgaJInternational Pegfilgrastim 749 Study GroupA randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapyAnn Oncol2003141293512488289
   PubMed Web of Science ®Google Scholar
• VoseJMCrumpMLazarusHRandomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphomaJ Clin Oncol200321351451912560443
   PubMed Web of Science ®Google Scholar
• HaoYChenJWangXZhuHRongZEffects of site-specific polyethylene glycol modification of recombinant human granulocyte colony-stimulating factor on its biologic activitiesBioDrugs200620635736217176123
   PubMed Web of Science ®Google Scholar
• HonjoETamadaTMaedaYCrystallization of a 2:2 complex of granulocyte-colony stimulating factor (GCSF) with the ligand-binding region of the GCSF receptorActa Crystallogr Sect F Struct Biol Cryst Commun200561Pt 8788790
   PubMedGoogle Scholar
• MolineuxGKinstlerOBriddellBA new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humansExp Hematol199927121724173410641590
   PubMed Web of Science ®Google Scholar
• LaytonJEHockmanHSheridanWPMorstynGEvidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factorBlood1989744130313072475185
   PubMed Web of Science ®Google Scholar
• JohnstonECrawfordJBlackwellSRandomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapyJ Clin Oncol200018132522252810893282
   PubMed Web of Science ®Google Scholar
• HolmesFAO’ShaughnessyJAVukeljaSBlinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancerJ Clin Oncol200220372773111821454
   PubMed Web of Science ®Google Scholar
• von MinckwitzGKümmelSdu BoisAGerman Breast GroupPegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO studyAnn Oncol200819229229817846019
   PubMed Web of Science ®Google Scholar
• HolmesFAJonesSEO’ShaughnessyJComparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancerAnn Oncol200213690390912123336
   PubMed Web of Science ®Google Scholar
• PettengellRGurneyHRadfordJAGranulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomized controlled trialBlood1992806143014361381626
   PubMed Web of Science ®Google Scholar
• KubistaEGlaspyJHolmesFAGreenMDHackettJNeumannTPegfilgrastim Study GroupBone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancerClin Breast Cancer20033639139812636878
   PubMedGoogle Scholar
• MartínMRodríguez-LescureARuizAGEICAM 9906 Study InvestigatorsRandomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancerJ Natl Cancer Inst20081001180581418505968
   PubMedGoogle Scholar
• RochéHFumoleauPSpielmannMSequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 TrialJ Clin Oncol200624365664567117116941
   PubMed Web of Science ®Google Scholar
• NCCN guidelines practice guidelines in oncology – v 2012
   Google Scholar
• SmithTJKhatcheressianJLymanGH2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guidelineJ Clin Oncol200624193187320516682719
   PubMed Web of Science ®Google Scholar
• AaproMSCameronDAPettengellREuropean Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working PartyEORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumoursEur J Cancer200642152433245316750358
   PubMed Web of Science ®Google Scholar
• PapaldoPLopezMMarollaPImpact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamideJ Clin Oncol200523286908691816129844
   PubMed Web of Science ®Google Scholar
• FalandryCCamponeMCartronGGuerinDFreyerGTrends in G-CSF use in 990 patients after EORTC and ASCO guidelinesEur J Cancer201046132389239820732287
   PubMed Web of Science ®Google Scholar
• BadalamentiGIncorvaiaLProvenzanoSBronteGLetoGFulfaroFMalteseGLenograstim in preventing hemotherapy-induced febrile neutropenia in patients with soft tissue sarcomaAnticancer Res2013;33267968423393367
   PubMed Web of Science ®Google Scholar
• SwansonGBergstromKStumpEMiyaharaTHerfindalETGrowth factor usage patterns and outcomes in the community setting: collection through a practice-based computerized clinical information systemJ Clin Oncol20001881764177010764438
   PubMed Web of Science ®Google Scholar
• RostiGAppropriate administration of Granulocyte-Colony Stimulating Factors in prophylaxis and treatment of chemotherapy-induced febrile neutropeniaRev Heal Car201232127142
   Google Scholar